BTIG Reiterates Buy on Palvella Therapeutics, Maintains $192 Price Target
Benzinga Newsdesk 9 months ago
NewsPrice TargetReiterationAnalyst Ratings
BTIG analyst Jeet Mukherjee reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Buy and maintains $192 price target.
BTIG analyst Jeet Mukherjee reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Buy and maintains $192 price target.